|
1
|
van der Bruggen P, Traversari C, Chomez P,
Lurquin C, De Plaen E, Van den Eynde BJ, Knuth A and Boon T: A gene
encoding an antigen recognized by cytolytic T lymphocytes on a
human melanoma. J Immunol. 178:2617–2621. 2007.PubMed/NCBI
|
|
2
|
Old LJ and Chen YT: New paths in human
cancer serology. J Exp Med. 187:1163–1167. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kienstra MA, Neel HB, Strome SE and Roche
P: Identification of NY-ESO-1, MAGE-1, and MAGE-3 in head and neck
squamous cell carcinoma. Head Neck. 25:457–463. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Müller-Richter UD, Dowejko A, Zhou W,
Reichert TE and Driemel O: Different expression of MAGE-A-antigens
in foetal and adult keratinocyte cell lines. Oral Oncol.
44:628–633. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Scanlan MJ, Simpson AJ and Old LJ: The
cancer/testis genes: Review, standardization, and commentary.
Cancer Immun. 4:12004.PubMed/NCBI
|
|
6
|
Simpson AJ, Caballero OL, Jungbluth A,
Chen YT and Old LJ: Cancer/testis antigens, gametogenesis and
cancer. Nat Rev Cancer. 5:615–625. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ferris RL: Progress in head and neck
cancer immunotherapy: Can tolerance and immune suppression be
reversed? ORL J Otorhinolaryngol Relat Spec. 66:332–340. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Doyle JM, Gao J, Wang J, Yang M and Potts
PR: MAGE-RING protein complexes comprise a family of E3 ubiquitin
ligases. Mol Cell. 39:963–974. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yang B, O'Herrin SM, Wu J, Reagan-Shaw S,
Ma Y, Bhat KM, Gravekamp C, Setaluri V, Peters N, Hoffmann FM, et
al: MAGE-A, mMage-b, and MAGE-C proteins form complexes with KAP1
and suppress p53-dependent apoptosis in MAGE-positive cell lines.
Cancer Res. 67:9954–9962. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ries J, Agaimy A, Vairaktaris E, Gorecki
P, Neukam FW, Strassburg LH and Nkenke E: Detection of MAGE-A
expression predicts malignant transformation of oral leukoplakia.
Cancer Invest. 30:495–502. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ries J, Agaimy A, Vairaktaris E, Kwon Y,
Neukam FW, Strassburg LH and Nkenke E: Evaluation of MAGE-A
expression and grade of dysplasia for predicting malignant
progression of oral leukoplakia. Int J Oncol. 41:1085–1093.
2012.PubMed/NCBI
|
|
12
|
Krauss E, Rauthe S, Gattenlöhner S,
Reuther T, Kochel M, Kriegebaum U, Kübler AC and Müller-Richter UD:
MAGE-A antigens in lesions of the oral mucosa. Clin Oral Investig.
15:315–320. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Piotti KC, Scognamiglio T, Chiu R and Chen
YT: Expression of cancer/testis (CT) antigens in squamous cell
carcinoma of the head and neck: Evaluation as markers of squamous
dysplasia. Pathol Res Pract. 209:721–726. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Laban S, Atanackovic D, Luetkens T, Knecht
R, Busch CJ, Freytag M, Spagnoli G, Ritter G, Hoffmann TK, Knuth A,
et al: Simultaneous cytoplasmic and nuclear protein expression of
melanoma antigen-A family and NY-ESO-1 cancer-testis antigens
represents an independent marker for poor survival in head and neck
cancer. Int J Cancer. 135:1142–1152. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hartmann S, Kriegebaum U, Küchler N,
Lessner G, Brands RC, Linz C, Schneider T, Kübler AC and
Müller-Richter UD: Efficacy of cetuximab and panitumumab in oral
squamous cell carcinoma cell lines: Prognostic value of MAGE-A
subgroups for treatment success. J Craniomaxillofac Surg.
41:623–629. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hartmann S, Kriegebaum U, Küchler N,
Brands RC, Linz C, Kübler AC and Müller-Richter UD: Correlation of
MAGE-A tumor antigens and the efficacy of various chemotherapeutic
agents in head and neck carcinoma cells. Clin Oral Investig.
18:189–197. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yarden Y and Shilo BZ: SnapShot: EGFR
signaling pathway. Cell. 131:10182007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Temam S, Kawaguchi H, El-Naggar AK,
Jelinek J, Tang H, Liu DD, Lang W, Issa JP, Lee JJ and Mao L:
Epidermal growth factor receptor copy number alterations correlate
with poor clinical outcome in patients with head and neck squamous
cancer. J Clin Oncol. 25:2164–2170. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Asami K and Atagi S: Epidermal growth
factor receptor tyrosine kinase inhibitors for non-small cell lung
cancer. World J Clin Oncol. 5:646–659. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Martins RG, Parvathaneni U, Bauman JE,
Sharma AK, Raez LE, Papagikos MA, Yunus F, Kurland BF, Eaton KD,
Liao JJ, et al: Cisplatin and radiotherapy with or without
erlotinib in locally advanced squamous cell carcinoma of the head
and neck: A randomized phase II trial. J Clin Oncol. 31:1415–1421.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shin DM, Zhang H, Saba NF, Chen AY,
Nannapaneni S, Amin AR, Müller S, Lewis M, Sica G, Kono S, et al:
Chemoprevention of head and neck cancer by simultaneous blocking of
epidermal growth factor receptor and cyclooxygenase-2 signaling
pathways: Preclinical and clinical studies. Clin Cancer Res.
19:1244–1256. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gross ND, Bauman JE, Gooding WE, Denq W,
Thomas SM, Wang L, Chiosea S, Hood BL, Flint MS, Sun M, et al:
Erlotinib, erlotinib-sulindac versus placebo: A randomized,
double-blind, placebo-controlled window trial in operable head and
neck cancer. Clin Cancer Res. 20:3289–3298. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Heo DS, Snyderman C, Gollin SM, Pan S,
Walker E, Deka R, Barnes EL, Johnson JT, Herberman RB and Whiteside
TL: Biology, cytogenetics, and sensitivity to immunological
effector cells of new head and neck squamous cell carcinoma lines.
Cancer Res. 49:5167–5175. 1989.PubMed/NCBI
|
|
24
|
Hartmann S, Seher A, Brands RC, Linz C,
Lessner G, Böhm H, Kübler AC and Müller-Richter UD: Influence of
epidermal growth factor receptor expression on the cetuximab and
panitumumab response rates of head and neck carcinoma cells. J
Craniomaxillofac Surg. 42:1322–1328. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mukohara T, Engelman JA, Hanna NH, Yeap
BY, Kobayashi S, Lindeman N, Halmos B, Pearlberg J, Tsuchihashi Z,
Cantley LC, et al: Differential effects of gefitinib and cetuximab
on non-small-cell lung cancers bearing epidermal growth factor
receptor mutations. J Natl Cancer Inst. 97:1185–1194. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Su S, Minges JT, Grossman G, Blackwelder
AJ, Mohler JL and Wilson EM: Proto-oncogene activity of melanoma
antigen-A11 (MAGE-A11) regulates retinoblastoma-related p107 and
E2F1 proteins. J Biol Chem. 288:24809–24824. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mollaoglu N, Vairaktaris E, Nkenke E,
Neukam FW and Ries J: Expression of MAGE-A12 in oral squamous cell
carcinoma. Dis Markers. 24:27–32. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hou SY, Sang MX, Geng CZ, Liu WH, Lü WH,
Xu YY and Shan BE: Expressions of MAGE-A9 and MAGE-A11 in breast
cancer and their expression mechanism. Arch Med Res. 45:44–51.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Quesnelle KM and Grandis JR: Dual kinase
inhibition of EGFR and HER2 overcomes resistance to cetuximab in a
novel in vivo model of acquired cetuximab resistance. Clin Cancer
Res. 17:5935–5944. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yonesaka K, Zejnullahu K, Okamoto I, Satoh
T, Cappuzzo F, Souglakos J, Ercan D, Rogers A, Roncalli M, Takeda
M, et al: Activation of ERBB2 signaling causes resistance to the
EGFR-directed therapeutic antibody cetuximab. Sci Transl Med.
3:99ra862011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Rosenthal EL, Chung TK, Carroll WR,
Clemons L, Desmond R and Nabell L: Assessment of erlotinib as
adjuvant chemoprevention in high-risk head and neck cancer
patients. Ann Surg Oncol. 21:4263–4269. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Jaiswal G, Jaiswal S, Kumar R and Sharma
A: Field cancerization: Concept and clinical implications in head
and neck squamous cell carcinoma. J Exp Ther Oncol. 10:209–214.
2013.PubMed/NCBI
|
